These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37407670)

  • 1. A harmonized resource of integrated prostate cancer clinical, -omic, and signature features.
    Laajala TD; Sreekanth V; Soupir AC; Creed JH; Halkola AS; Calboli FCF; Singaravelu K; Orman MV; Colin-Leitzinger C; Gerke T; Fridley BL; Tyekucheva S; Costello JC
    Sci Data; 2023 Jul; 10(1):430. PubMed ID: 37407670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. curatedPCaData: Integration of clinical, genomic, and signature features in a curated and harmonized prostate cancer data resource.
    Laajala TD; Sreekanth V; Soupir A; Creed J; Calboli FC; Singaravelu K; Orman M; Colin-Leitzinger C; Gerke T; Fidley BL; Tyekucheva S; Costello JC
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes.
    Barfeld SJ; East P; Zuber V; Mills IG
    BMC Med Genomics; 2014 Dec; 7():513. PubMed ID: 25551447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.
    Stuchbery R; Macintyre G; Cmero M; Harewood LM; Peters JS; Costello AJ; Hovens CM; Corcoran NM
    Oncotarget; 2016 May; 7(21):31384-92. PubMed ID: 27120785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
    Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
    Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
    Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
    Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
    Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.
    Alshalalfa M; Schliekelman M; Shin H; Erho N; Davicioni E
    Biol Cell; 2015 Jul; 107(7):232-44. PubMed ID: 25900404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.
    Crea F; Quagliata L; Michael A; Liu HH; Frumento P; Azad AA; Xue H; Pikor L; Watahiki A; Morant R; Eppenberger-Castori S; Wang Y; Parolia A; Lennox KA; Lam WL; Gleave M; Chi KN; Pandha H; Wang Y; Helgason CD
    Mol Oncol; 2016 May; 10(5):693-703. PubMed ID: 26809501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.
    Boufaied N; Takhar M; Nash C; Erho N; Bismar TA; Davicioni E; Thomson AA
    J Pathol; 2019 Dec; 249(4):411-424. PubMed ID: 31206668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
    Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
    Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
    BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
    Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.
    Amaro A; Esposito AI; Gallina A; Nees M; Angelini G; Albini A; Pfeffer U
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):657-71. PubMed ID: 24477410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.